A Phase 4 interventional study of Normal Saline (Rocuronium 0 mg/kg) and Rocuronium 0.3 mg/kg in Airway Management, Neuromuscular Blockade and General Anesthesia, sponsored by Korea University Guro Hospital. Not yet recruiting. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by Korea University Guro Hospital · Phase 4, Interventional, and Other
This prospective, randomized, double-blind study aims to evaluate the effect of different degrees of neuromuscular blockade on the performance of a video laryngeal mask airway (LMA) during general anesthesia. Participants will be randomly assigned to receive rocuronium at 0, 0.3, or 0.6 mg/kg, corresponding to 0, 1, or 2 times the ED95, respectively. The primary outcome is oropharyngeal leak pressure measured after LMA insertion. Secondary outcomes include LMA insertion conditions, insertion time and number of attempts, laryngeal view, respiratory parameters, and postoperative airway-related complications.
Korea University Guro Hospital is the lead sponsor of 89 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive rocuronium 0 mg/kg (0 × ED95) before video LMA insertion.
Other: Normal Saline (Rocuronium 0 mg/kg)
Participants receive rocuronium 0.3 mg/kg (1 × ED95) before video LMA insertion.
Drug: Rocuronium 0.3 mg/kg
Participants receive rocuronium 0.6 mg/kg (2 × ED95) before video LMA insertion.
Drug: Rocuronium 0.6 mg/kg
Normal saline is administered intravenously as the control study drug before video LMA insertion.
Drug page: Rocuronium
Rocuronium 0.3 mg/kg (1 × ED95) is administered intravenously before video LMA insertion.
Drug page: Rocuronium
Rocuronium 0.6 mg/kg (2 × ED95) is administered intravenously before video LMA insertion.
Oropharyngeal Leak Pressure (OLP)
Oropharyngeal leak pressure will be measured 5 minutes after successful video LMA insertion and compared among the three neuromuscular blockade groups. OLP is expressed in cmH2O.
Time frame: 5 minutes after successful video LMA insertion
Oropharyngeal Leak Pressure at Later Time Points
Time frame: 15 and 30 minutes after successful video LMA insertion
Number of LMA Insertion Attempts
The number of attempts required for successful video LMA insertion will be recorded. A maximum of two insertion attempts is permitted. Failure will be recorded if successful insertion is not achieved after two attempts.
Time frame: During anesthetic induction before surgery, assessed for up to 5 minutes
LMA Insertion Time
LMA insertion time will be measured in seconds from mouth opening to confirmation of the first capnographic waveform.
Time frame: During anesthetic induction before surgery, assessed for up to 5 minutes
Laryngeal View Grade
The laryngeal view obtained through the video LMA will be graded on a 4-point scale. The need for real-time adjustment and any change in laryngeal view after adjustment will also be recorded.
Time frame: Immediately after successful video LMA insertion
Neuromuscular Blockade at LMA Insertion
Neuromuscular response will be recorded immediately before video LMA insertion using train-of-four monitoring, including TOF count and/or quantitative twitch response according to the available monitor.
Time frame: Immediately before video LMA insertion
Number of Participants With Sore Throat, Hoarseness, and Dysphagia
The presence or absence of sore throat, hoarseness, and dysphagia will be assessed separately for each participant.
Time frame: Postoperatively in the PACU and at 24 hours after surgery
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Feb 2027, 5 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rocuronium
Korea University Guro Hospital